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Abstract  
Type 2 diabetes (T2DM) promotes premature atherosclerosis and inferior prognosis after 
arterial reconstruction. Vascular smooth muscle cells (SMC) respond to patho/physiological 
stimuli, switching between quiescent contractile and activated synthetic phenotypes under 
the control of microRNAs (miRs) that regulate multiple genes critical to SMC plasticity. The 
importance of miRs to SMC function specifically in T2DM is unknown. This study was 
performed to evaluate phenotype and function in SMC cultured from non-diabetic and T2DM 
patients, to explore any aberrancies and investigate underlying mechanisms. Saphenous 
vein SMC cultured from T2DM patients (T2DM-SMC) exhibited increased spread cell area, 
disorganised cytoskeleton and impaired proliferation relative to cells from non-diabetic 
patients (ND-SMC), accompanied by a persistent, selective up-regulation of miR-143 and 
miR-145. Transfection of premiR-143/145 into ND-SMC induced morphological and 
functional characteristics similar to native T2DM-SMC; modulating miR-143/145 targets 
Kruppel-like factor 4, alpha smooth muscle actin and myosin VI. Conversely, transfection of 
antimiR-143/145 into T2DM-SMC conferred characteristics of the ND phenotype. Exposure 
of ND-SMC to transforming growth factor beta (TGFβ) induced a diabetes-like phenotype; 
elevated miR-143/145, increased cell area and reduced proliferation. Furthermore, these 
effects were dependent on miR-143/145. In conclusion, aberrant expression of miR-143/145 
induces a distinct saphenous vein SMC phenotype that may contribute to vascular 
complications in patients with T2DM, and is potentially amenable to therapeutic 
manipulation.  
 
Keywords: Type 2 diabetes, smooth muscle cell, microRNA-143/145, TGFβ, differentiation 
 
 
 
 
 
 
 
 
 
 
Glossary: α-SMA, alpha smooth muscle actin; CABG, coronary artery bypass grafting; 
CaMKII, calcium/calmodulin-dependent protein kinase 2 delta; CHD, coronary heart 
disease; DMEM, Dulbecco’s modified eagle medium; FCS, foetal calf serum; FGM, full 
growth medium; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IGF-1R, insulin-like 
growth factor receptor 1; IL-1α, interleukin-1 alpha; IRS-1, insulin receptor substrate 1; 
KLF4, Kruppel-like factor 4; miR, microRNA; ND, non-diabetic; PKCε, protein kinase C 
epsilon; SMC, smooth muscle cell; SV, saphenous vein; T2DM, type 2 diabetes; TGFβ, 
transforming growth factor beta; TNF-α, tumour necrosis factor alpha. 
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1. Introduction 
Insulin resistance leading to type 2 diabetes mellitus (T2DM) confers a risk equivalent to 15 
years of aging [1]. Early diagnosis is difficult as the disease is initially symptomless; hence 
up to half of patients have evidence of cardiovascular complications by the time diabetes is 
confirmed [2]. Such individuals are vulnerable to accelerated atherosclerosis and premature 
coronary heart disease (CHD), and revascularisation procedures are also problematic with 
disappointing long-term outcomes [3]. Despite this, coronary artery bypass grafting (CABG) 
using autologous saphenous vein (SV) remains the optimal treatment for diabetes patients 
with multivessel disease, following which graft failure is a significant problem [4,5]. 
Importantly, structural abnormalities in SV of diabetic subjects are evident pre-operatively, 
the severity of which appears to be associated with poor glycaemic control [6].  
 Clinical trials revealed that intensive control of hyperglycaemia is effective in 
retarding and preventing the microvascular complications of diabetes [7] yet medium term, 
macrovascular complications persist particularly in patients with diabetes and active CHD 
[7,8]. Development of vascular complications as a result of prior exposure to 
hyperinsulinaemia and hyperglycaemia in diabetes appears to confer persistent alterations in 
vascular gene expression, indicative of epigenetic modulation that is referred to as metabolic 
memory (reviewed in [9]). Elucidating molecular mechanisms that underlie this phenomenon 
is therefore of great interest.  
Smooth muscle cells (SMC) of blood vessel walls switch between differentiated and 
dedifferentiated phenotypes in response to local cues. Phenotypic switching is essential 
during vascular development, repair and adaptation, but also contributes to progression of 
atherosclerosis and bypass graft failure [10]. Effective adaptation to arterial environments 
early after implantation is a determinant of the long-term patency of SV grafts [11]; hence the 
ability of SMC to retain plasticity during adaptation and “arterialisation” is vital. Failure of 
SMC to respond dynamically to conditions of increased flow and pressure early after grafting 
conceivably jeopardises the longer-term patency of SV used as arterial bypass grafts [12]. 
 We previously reported that human SV-SMC cultured from patients with T2DM were 
phenotypically and functionally distinct from those of non-diabetic individuals [13]. Key 
features were rhomboid morphology, F-actin fragmentation and reduced proliferation 
capacity [13], any of which can conceivably contribute to impaired vessel remodelling in 
diabetic patients following bypass grafting.  
 Recent evidence suggests that changes in SMC phenotype and function during 
vascular remodelling are controlled by epigenetic mechanisms, including microRNAs (miRs) 
(reviewed in [14]). These small non-coding RNAs act in a tissue- and cell-specific manner, 
regulating target genes by inducing mRNA degradation or translational repression [15]. 
Altered levels of miRs have been associated with a number of cardiovascular complications 
in diabetes (reviewed in [16,17]), however little is known about how diabetes per se 
modulates phenotype and function of vascular SMC. Dysregulation of miRs induced by the 
metabolic milieu may contribute to altered gene expression and SMC aberrancies in 
individuals with T2DM [18].  
In this study, we discovered that SMC cultured from T2DM patients expressed 
increased levels of miR-143 and -145 and elucidated roles for these miRs in driving cellular 
dysfunction.  
 
2. Materials and methods 
 
2.1 Cell culture - SMC were cultured as we previously described from explants of SV [19] 
obtained from patients without known diabetes (ND-SMC), or with diagnosed type 2 diabetes 
(T2DM-SMC) receiving oral therapy alone or oral therapy plus insulin. All patients were 
undergoing elective CABG surgery at the Leeds General Infirmary. Local ethical committee 
approval and informed, written patient consent was obtained and the study conformed to the 
principles outlined in the Declaration of Helsinki.  
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2.2 Cell area measurements – Cells were imaged at x100 magnification and the boundaries 
of 50 subconfluent individual cells per patient were traced. Spread cell areas were calculated 
using Image J software (http://imagej.nih.gov/ij/). For each patient population, cell areas 
were ordered (1000 µm2 increments) from which a distribution profile and average cell area 
was determined.  
 
2.3 Rhodamine phalloidin immunofluorescence - Cells were cultured for 48 h in full growth 
medium (FGM) and fixed in 4% paraformaldehyde. F-actin fibres were labelled using 
rhodamine phalloidin (1:40) as previously described [20]. 
 
2.4 Quantitative real-time RT-PCR – Cellular RNA was extracted and real-time RT-PCR was 
performed using intron-spanning human ACTA2 primers and Taqman probes (Applied 
Biosystems, Foster City, California) and Applied Biosystems 7500 Real-Time PCR System. 
Data are expressed as percentage of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
endogenous control mRNA expression using the formula 2-∆CT x 100. 
 
2.5 Proliferation assays - Proliferation assays were performed over 7 days as previously 
described [13].  
 
2.6 Quantification of miR expression levels - RNA was isolated and relative expression 
levels of miR-125b, -133a, -143 and -145 determined using specific TaqMan microRNA 
assays (Applied Biosystems, Foster City, California) and real-time PCR according to 
manufacturer’s protocols. Data analysis was performed using the comparative CT method, 
and values normalised to U6 expression.  
 
2.7 Transfection of premiRs and antimiRs - Subconfluent cells were transfected with 
premiRs (30 nM) or antimiRs (60 nM) for miR-143 and miR-145, and associated negative 
controls. Endpoints were measured 72 h later (cell morphology, RNA isolation, F-actin 
staining) or proliferation assays performed. 
 
2.8 Immunoblotting - SMC were transfected with relevant premiRs, antimiRs or negative 
controls. Following transfection, whole cell homogenates were sequentially prepared 3, 5, 7 
and 10 days later. Protein lysates were immunoblotted for alpha-smooth muscle actin (α-
SMA), calcineurin (PPP3CA), calcium/calmodulin-dependent protein kinase 2 delta 
(CaMKIIδ), kruppel-like factor 4 (KLF4), insulin-like growth factor-1 receptor (IGF-1R), insulin 
receptor substrate-1 (IRS-1), myosin VI or protein kinase C epsilon (PKCε), as described 
previously [21]. GAPDH acted as a loading control. Selected proteins were also investigated 
from native ND- and T2DM-SMC cultured under identical conditions. 
 
2.9 Induction of miR expression – SMC were treated with high glucose (25 mM), insulin (100 
nM), proinflammatory cytokines (a combination of interleukin (IL)-1α and tumour necrosis 
factor (TNF)-α, both 10 ng/mL), or TGFβ (0.1-10 ng/mL) in low serum (0.4%)-containing 
medium for 48 h. Cells maintained in 5.5 mM glucose for the same timeframe acted as 
controls. RNA was extracted and miR-143 and miR-145 expression levels determined. 
 
2.10 TGFβ signalling blockade – For functional experiments, T2DM-SMC were treated with 
10 µg/ml anti-TGFβRII neutralising antibody or control polyclonal goat IgG for 48 h after 
which end-points were measured (cell morphology, RNA isolation, F-actin staining). For 
proliferation, media was refreshed after 48 h and final cell counts performed after 96 h. Data 
were expressed as increase in cell number between days 0 and 4. 
 
2.11 Chronic TGFβ treatment – ND-SMC were treated daily with 1 ng/ml TGFβ or vehicle for 
7 d in media containing 2.5% FCS. TGFβ was then withdrawn and culture was continued for 
a further 7 d. Cell area measurements were performed and RNA was extracted on days 7, 
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11 and 14. Data were expressed as fold change in miR-143/145 levels in cells treated with 
TGFβ versus vehicle at each time point. 
 
2.12 Statistical analysis - Results are presented as mean  SEM with n representing the 
number of experiments on cells from different patients. Any potential differences in 
cardiovascular therapies between ND and T2DM-SMC were evaluated using contingency 
tables and two-sided Fishers exact test. All experimental data were tested for normality and 
analysed using parametric or non-parametric unpaired ratio t-tests, one-way ratio ANOVA or 
two-way ANOVA with post-hoc test as appropriate (GraphPad Prism software). P<0.05 was 
considered statistically significant. 
 
3. Results 
 
3.1 Subject characteristics 
SV-SMC were cultured from a total of 130 patients recruited between August 2008 and 
January 2014. The mean age of non-diabetic individuals (n=77, 84% male) was 65.2±1.05 
(range 42-83) years. For T2DM patients (n=53, 100% male) the mean age was 63.0±1.4 
(range 34-85) years. The lack of female subjects in the T2DM group was a reflection of the 
predominance of male gender undergoing CABG surgery and greater prevalence of T2DM in 
male subjects, together with the retrospective analysis of subject characteristics. 
More detailed data were acquired for 57 of the non-diabetic and 44 of the T2DM patients. 
Whilst plasma levels of LDL-cholesterol and creatinine were similar between cohorts, fasting 
glucose and HbA1c were significantly elevated in the diabetic patients (Table I). All T2DM 
patients were receiving oral therapy (metformin/sulfonylureas/gliptins), and 30% of these 
were also receiving insulin (Table II). Routine cardiovascular medications were similar in 
both cohorts (Table II). 
 
Table I. Biochemical characteristics of patients from whom SV-SMC were cultured.  
 
Plasma levels of glucose, glycated haemoglobin (HbA1c), LDL cholesterol (LDL-C) and 
creatinine in non-diabetic and T2DM patients at the time of surgery. Data are expressed as 
median (range). Whilst cholesterol and creatinine levels were similar, both fasting glucose 
and HbA1c were significantly elevated in the diabetic patients (Mann-Whitney unpaired t-
test, NS - not statistically significant).  
 
 
 
 
 
 
 No diabetes Type 2 diabetes P value 
Fasting glucose (mmol/L) 5.4 (4.9-9.9) 8.1 (4.3-15.7) ***P<0.001 
HbA1c (mmol/mol) 
HbA1c (%) 
42.5 (32.0-56.0) 
6.04 (5.08-7.27) 
66.0 (32.0-94.0) 
8.19 (5.08-10.75) 
***P<0.001 
***P<0.001 
LDL-C (mmol/L) 3.9 (2.4-7.8) 3.9 (2.2-6.6)     P=0.97 
Creatinine (µmol/L) 97.0 (50.0-147.0) 100.7 (54.0-203.0)     P=0.57 
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Table II. Clinical characteristics of patients from whom SV-SMC were cultured.  
 No diabetes Type 2 diabetes P value 
Oral therapy 
Metformin 
+ Sulfonylurea 
+ Gliptin 
 
- 
- 
- 
 
85.6% 
21.4% 
7.1% 
 
- 
- 
- 
Oral + insulin therapy - 30.8% - 
Statins 80.0% 78.6% P=1.00 
ACE inhibitors/ARBs 91.0% 73.3% P=0.37 
β-blockers 92.8% 80.0% P=0.37 
Antiplatelet/anticoagulant  84.6% 93.8% P=0.61 
Diuretics 33.3% 40.0% P=1.00 
 
Comparison of drug therapies between the patient cohorts. Typical cardiovascular 
treatments: cholesterol-lowering drugs (statins), angiotensin-modulating agents (ACE-I, 
ARBs), beta adrenergic receptor blockers (β-blockers), anticoagulation therapies and 
diuretics were common to both patient groups. All diagnosed T2DM patients were receiving 
oral therapies (predominantly metformin) with some patients also receiving sulfonylureas or 
gliptins. Of these, 30% were also receiving insulin therapy.  
 
 
3.2 SV-SMC from T2DM donors exhibit distinct morphology and impaired proliferation  
In contrast to the spindle morphology of ND-SMC, cells cultured from T2DM patients were 
predominantly rhomboid (Fig. 1A), consistent with our previous report [13]. The majority of 
ND-SMC had spread areas <10,000 µm2 (Fig. 1B). In contrast, T2DM-SMC displayed 
greater morphological heterogeneity (Fig. 1B) reflected by mean spread cell area ~60% 
larger than ND-SMC (Fig. 1C). There was a trend towards increased ACTA2 mRNA levels 
(the gene encoding -SMA, a marker of SMC differentiation) in T2DM-SMC although this did 
not reach statistical significance (Fig. 1D). Additionally, T2DM-SMC exhibited a disrupted F-
actin cytoskeleton with truncated fibres compared to ND-SMC (Supplementary Fig. 1A) and 
proliferated more slowly than ND-SMC (Supplementary Fig. 1B), consistent with our 
previous observations [13]. These divergent profiles appear specific to SV-SMC since we 
recently observed no disparity in proliferation rate of SMC cultured from internal mammary 
artery of ND and T2DM patients [22].  
 
3.3 Expression of miR-143 and miR-145 is elevated in T2DM-SMC  
Dysregulated expression of miRs has been implicated in T2DM complications [16,17] 
Therefore we determined expression levels of “candidate” miRs (125b, 133a, 143 and 145) 
using quantitative RT-PCR (Fig. 1E). MiR-143 and -145 are highly expressed in SMC in 
vascular walls where they reportedly regulate SMC homeostasis and differentiation [23,24]. 
MiR-125b and miR-133a were investigated given the reported increase in miR-125b in 
vascular SMC of db/db mice [25] and the contribution of miR-133a to abnormal cardiac 
function in a rabbit model of diabetes [26]. Neither miR-125b nor miR-133a levels differed 
between SMC populations, but miR-143 and miR-145 were both elevated (~60%) in T2DM-
SMC (Fig. 1E). Absolute miR-145 levels were ~10-fold higher than miR-143 in both ND- and 
T2DM-SMC, but there was a strong correlation between them (Fig. 1F). Expression levels of 
miR-143 and -145 remained stable throughout passaging (Supplementary Fig. 2). 
 
3.4 MiR-143 and miR-145 regulate SV-SMC morphology 
To determine whether miR-143 and/or -145 were driving changes in SV-SMC morphology, 
we artificially manipulated them by transfection with premiRs or antimiRs (Fig. 2). As miR-
143 and miR-145 were proportionally higher in T2DM-SMC we used antimiRs to reduce 
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expression levels in T2DM-SMC. Conversely, we used premiRs to increase expression in 
ND-SMC. Transfection of ND-SMC with premiR-143 and -145 (alone or combined) led to a 
36% increase in spread cell area (Fig. 2A) and the appearance of truncated F-actin fibres 
similar to those in native T2DM-SMC (Fig. 2B). In T2DM-SMC the combination of antimiR-
143+145 together was required to modulate spread cell area (~36% reduction) (Fig. 2C) and 
also visibly reduced the abundance of truncated F-actin fibres (Fig. 2D). 
 
3.5 MiR-145 regulates SMC proliferation 
To determine whether altered miR-143/145 expression contributed to the divergent SMC 
proliferation between non-diabetic and T2DM patients, appropriately transfected cells were 
incorporated into proliferation assays. Overexpression of premiR-143+145 reduced 
proliferation of ND-SMC by 35% (P<0.05, Fig. 2E). Conversely, transfection of T2DM-SMC 
with antimiR-143+145 increased cell proliferation by 50% (P<0.05, Fig. 2F). In both cases, 
the functional effect on proliferation was attributable solely to miR-145; manipulating miR-
143 alone was ineffective (Fig. 2E,F).  
 
3.6 Identification of miR-143/145 targets in SV-SMC 
We used immunoblotting to investigate protein targets potentially responsible for mediating 
the effects of altered miR-143/145 expression on SMC function. Six validated miR-143 and -
145 target genes whose activities are known to regulate SMC function and/or phenotype 
(KLF4, myosin VI, CaMKIIδ, IGF-1R, IRS-1 and PKCε) [27-30] were explored. α-SMA was 
studied because endogenous ACTA2 mRNA levels were generally higher in T2DM-SMC 
(Fig. 1D) and there was a strong correlation between miR-145 and ACTA2 mRNA levels 
(P<0.001, r2=0.6324, n=20). Initial experiments revealed that protein levels of CaMKII, IRS-
1 and PKCε were unaffected by miR-143+5 modulation at any time point (Supplementary 
Fig. 3). For targets where some regulation was evident, day 7 post-transfection was optimum 
for evaluating protein expression following premiR transfection in ND-SMC, and day 10 for 
antimiR transfected T2DM-SMC (Supplementary Fig. 4).  
In ND-SMC, protein levels of α-SMA (a marker of differentiation) increased in 
response to elevating miR-143/145 levels (premiR-143/145) alone or combined, whilst miR 
inhibition using antimiR-143+145-transfected T2DM-SMC exhibited >40% decrease in α-
SMA expression. In each case, modulation appeared predominantly attributable to miR-145 
(Fig. 3A). KLF4 (a potential direct target of miR-145) protein levels followed the opposite 
pattern; they were reduced by either premiR-143 or premiR-145 in ND-SMC and increased 
following transfection of either antimiR-143 or -145 (Fig. 3A). Although both premiR-143 and 
-145 induced IGF-1R protein expression, neither antimiR reduced IGF-1R protein levels (Fig. 
3A). For myosin VI, a small yet consistent reduction was observed following premiR 
transfection with a comparable increase in response to antimiRs (Fig. 3A).  
Immunoblotting of lysates from native ND- and T2DM-SMC revealed inherent 
variability in target protein levels between samples, although there was a trend towards 
increased α-SMA and decreased KLF4 protein levels in T2DM-SMC (Fig. 3B,C), in 
agreement with the premiR/antimiR studies (Fig. 3A). There were no discernible differences 
in IGF-1R expression (Fig. 3D), but myosin VI expression was significantly lower in native 
T2DM-SMC than in ND-SMC (Fig. 3E) compatible with the effect of artificially manipulating 
miR-143 and -145 levels (Fig. 3A). Expression levels of miR-143 and miR-145 were 
quantified in RNA extracted from cells from the same patient donors as the protein samples; 
demonstrating that miR-143 and miR-145 were significantly elevated in the T2DM-SMC used 
specifically in these experiments (Fig. 3F,G), and in agreement with data in Fig. 1E and 
Supplementary Fig. 2. 
 
3.7 TGFβ modifies miR-143/145, cell area and proliferation 
In order to identify the molecular mechanisms underlying elevated miR-143/145 in T2DM-
SMC, we used a variety of “diabetogenic” stimuli to investigate their ability to increase miR-
143/145 levels in ND-SMC (Fig. 4). Whilst glucose, insulin and inflammatory cytokines (IL-1 
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and TNF) did not induce miR-143 or -145 expression over the timeframe studied, TGFβ (10 
ng/mL) provoked a 2.5-fold increase in miR-143 and -145 after 48 h (Fig. 4A,B). This effect 
was concentration-dependent (data not shown), being maximal at 1 ng/mL TGFβ. Treatment 
of ND-SMC with 1 ng/mL TGFβ increased spread cell area by 57% (Fig. 4C,D), increased 
fragmented F-actin fibres (Fig.4E), and impaired cell proliferation by 37% (Fig. 4F).  
3.8 MiR-143/145 modulate effects of TGFβ on ND-SMC function 
To investigate the relationship between miR-143+145 and TGFβ-mediated cellular effects, 
ND-SMC were transfected with antimiRs prior to TGFβ stimulation. In control (antimiR 
negative) cells, TGFβ induced a 48% increase in cell area whilst in antimiR-143+145-
transfected cells this increase was prevented (P<0.01, Fig. 5A,B). Similarly, TGFβ reduced 
proliferation in control cells by 65%, an effect completely negated in antimiR-145-transfected 
cells (P<0.01, Fig. 5C). These data suggest that increased cell area and reduced 
proliferation rate in response to TGFβ is mediated via miR-143/5. 
 We then explored whether inhibition of TGFβ signalling per se could reinstate ND 
characteristics to T2DM-SMC. A TGFβRII neutralising antibody used at a concentration that 
abrogated TGFβ-induced Smad3 phosphorylation (Fig.5D) did not modulate T2DM-SMC cell 
morphology (Fig. 5E,F), F-actin organisation (Fig. 5G), proliferation (Fig. 5H) or expression 
of miR-143 or -145 (Fig. 5I). Thus although we show that TGFβ modifies cellular properties 
through miR-143 and -145, these effects are not readily reversible in cultured cells. 
3.9 Chronic exposure to TGFβ exerts persistent effects on ND-SMC phenotype 
To investigate whether long-term application of TGFβ could induce persistent changes in 
cellular phenotype even after its removal, ND-SMC were treated for 7 d with TGFβ and then 
cultured for an additional 7 d without TGFβ treatment. TGFβ induced a 1.9-fold increase in 
cell area after 7 days (Fig. 6A,B), which was maintained after the removal of TGFβ for at 
least one further week (Fig. 6A,B). In parallel, TGFβ induced a 2.5-fold and 2.2-fold increase 
in miR-143 and miR-145 expression respectively after 7 days (Fig. 6C,D). However in 
contrast to the persistent effect on cell morphology, expression of miR-143 and miR-145 
returned towards basal levels following withdrawal of TGFβ.  
 
 
4. Discussion 
 
4.1 Human saphenous vein smooth muscle cells from diabetic patients exhibit a distinct and 
persistent phenotype 
Structural anomalies and varying degrees of fibrotic thickening have been observed in intact 
SV prior to use as bypass grafts [31-33]. In addition, pre-operative abnormalities have been 
detected in SV harvested from T2DM patients [6] but characterisation at the level of the SMC 
has not previously been reported. To our knowledge this is the first study to associate 
dysregulation of miR-143/145 with aberrancies of SV-SMC phenotype and function specific 
to patients with T2DM. 
The principal function of differentiated vascular SMC is contraction, yet their 
remarkable plasticity confers an ability to undergo phenotypic switching. Vessel remodelling 
in response to altered blood flow, and repair mechanisms following vascular injury are 
characterised by dedifferentiated, synthetic SMC with reduced expression of differentiated 
contractile markers (reviewed in [10]). These classical phenotypes represent extremes of the 
differentiation scale although SMC may exist in intermediate states [34]. Our data indicate a 
distinct phenotype in T2DM-SMC, exhibiting both classical differentiated and dedifferentiated 
characteristics that likely compromise remodelling of venous grafts by preventing  dynamic 
structural changes that are necessary early after implantation to withstand arterial 
haemodynamic forces (“arterialisation”) [11]. Importantly, this adaptive phase is temporally 
distinct from ensuing maladaptive intimal thickening and occlusion [35], and requires 
maintenance of SMC plasticity to execute appropriate cellular function, including  
proliferation [12]. The data we present therefore is in the context of early graft failure through 
9 
 
inadequate arterialisation rather than the subsequent development of intimal hyperplasia. In 
support of this proposal, recent translational studies demonstrated that loss of primary 
patency in SV grafts was associated with a failure to remodel efficiently within the first 30 
days [36].  
We discovered increased levels of miR-143 and -145 in SV-SMC cultured from 
T2DM patients that persisted in long-term culture and in the absence of deleterious stimuli. 
This modest (1.6-fold) elevation is comparable with other studies that have investigated miR 
expression in atherosclerosis in native tissues and cells [37-39]. Over-expression of miR-145 
(and to a lesser degree miR-143) in ND-SMC increased cell area, disturbed F-actin 
dynamics and impaired proliferation reminiscent of native T2DM-SMC. Conversely, inhibition 
of miR-143+145 in T2DM-SMC reduced cell area, restored F-actin organisation and 
increased proliferation to a level indistinguishable from native ND-SMC. Patients with T2DM 
have elevated plasma levels of TGFβ [40] and we demonstrated that TGFβ modulated miR-
143/145 expression, cell area and proliferation akin to the native phenotype of T2DM-SMC; 
effects mediated in part via miR-143+145. Our main findings are summarised in Fig. 7. 
  
4.2 MiR expression and function is cell type and species-specific  
Animal studies have shown that miR-143/145 expression is upregulated in the liver of mouse 
models of obesity [41], and downregulated in SMC of rats with metabolic syndrome [42]. No 
differences in plasma levels of miR-143/145 were observed in a study of T2DM and non-
diabetic patients [43]; however the source of plasma miRs is most likely circulating and 
endothelial cells rather than SMC. Our study is therefore the first to discover elevated 
expression levels of miR-143 and -145, specifically in SV-SMC from T2DM patients, 
conferring characteristics that persist in culture and throughout passaging. 
 MiR-143 and -145 are SMC-enriched miRs, yet expression is reported in other 
tissues such as liver, adipose tissue and plasma [41,43]. Both are transcribed from the same 
locus in a bicistronic transcript unit [27] and accordingly we observed similar fold increases 
in expression of miR-143 and -145. Relative expression levels of miR-145 were 10-fold 
higher than miR-143, consistent with previous reports [44].  
We observed no difference in expression of miR-125b and miR-133a between SV-
SMC from human non-diabetic and T2DM patients, despite previous associations with T2DM 
in cardiovascular cells of animal models [25,26,45]. These anomalies may therefore highlight 
species-, tissue- or cell type-specific differences. Of particular relevance is a recent report 
that miR-145 expression was reduced in coronary SMC of rats with metabolic syndrome and 
associated with impaired collateral growth [42]. Of critical importance however, and of direct 
relevance to our study, was a demonstration that whilst reinstatement of physiological miR-
145 levels completely restored collateral growth, overexpression of miR-145 severely 
compromised this function, underscoring the necessity for “physiological” levels of miR-145 
for normal vascular structure and function [42]. 
 
4.3 miR-143 and -145 modulate SV-SMC morphology and function 
We observed an association between T2DM, larger SMC size and increased expression 
levels of miR-143 and -145, concurring with reports that aortic SMC from diabetic rats have 
larger cytoplasmic volumes than their non-diabetic counterparts [46], and that vascular SMC 
of miR-143/145 knockout mice are smaller than those of wild-type littermates [47]. We also 
showed that manipulation of miR-143 and miR-145 regulated actin expression and 
organisation. Interestingly, a number of regulators of actin dynamics are known targets of 
these miRs [43,47]. Through the promotion of contractile gene expression, miR-145 
overexpression has been shown to inhibit the development of neointimal hyperplasia in 
injured murine arteries [23,48]. Interestingly in a very small human study, miR-145 
downregulation in “traditionally” harvested SV was associated with poorer patency than in 
veins harvested using a “no touch” technique where miR-145 levels were reportedly higher 
[49].    
We previously reported that T2DM-SMC exhibit impaired proliferation rate [13]; 
results corroborated in the present study and additionally found to be characteristic of SV, 
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but not internal mammary artery. This impairment was effectively rescued by transfection 
with antimiR-145 and conversely, premiR-145 transfection into ND-SMC reduced 
proliferation. Manipulation of miR-143 in either SMC population was ineffective, indicating 
that specifically miR-145 modulates proliferative activity. In accordance with our findings, 
overexpression of miR-145 and to a lesser degree miR-143, suppressed proliferation of rat 
aortic [27] and human pulmonary artery SMC [50]. As the most abundantly expressed in the 
vasculature, miR-145 is associated with differentiated SMC [23] with apparent greater 
influence than miR-143 [44]. Reduced levels of miR-143/145 were observed in proliferative 
vascular SMC following carotid injury in a murine model [27]. However, no such differences 
were evident in cardiac muscle in the same animals, again highlighting the cell and tissue-
type specificity of miR expression, features that are potentially attractive for therapeutic miR 
manipulation.  
 
4.4 Identification of miR-143/145 targets in SV-SMC  
Our data suggest that overexpression of miR-145 reduced expression of KLF4 and 
increased expression of the differentiation marker α-SMA. In human pulmonary artery SMC, 
miR-143 or -145 overexpression downregulated KLF4, although the magnitude of effect was 
greater with miR-145 [44]. Lentiviral transfer of miR-145 into murine carotid arteries in vivo 
increased expression of markers of SMC differentiation, including α-SMA [27]. KLF4 is not 
expressed in healthy blood vessels but is rapidly induced following vascular injury where it is 
associated with transcriptional repression of SMC differentiation marker genes including α-
SMA [51]. Recent studies provide new evidence that loss of KLF4 and subsequent SMC 
differentiation is driven at least in part by miR-143/145 [27,47]. In the current study, whilst a 
trend towards increased α-SMA and decreased KLF4 in T2DM-SMC was apparent, this was 
not statistically significant. It is likely that the high inter-patient variation together with the 
semi-quantitative nature of immunoblotting were contributing factors. Myosin VI regulates 
cellular adhesion, endocytosis and gene transcription and of particular relevance to this 
study, has been shown to stabilise F-actin fibres [52,53]. It is plausible that the persistent 
disorganised F-actin cytoskeleton that we observed in T2DM-SMC may be related to 
reduced expression of myosin VI, although a more detailed study of the time course of this 
effect would be required. 
 
4.5 TGFβ up-regulates miR-143/145 and alters SV-SMC phenotype and function 
Upregulation of miR-143/145 could conceivably be caused by any number of factors within 
the diabetic milieu. Elevated concentrations of glucose, insulin and inflammatory cytokines 
reportedly modulate expression of various microRNAs [25,54,55]. We examined the effect of 
several stimuli on miR-143/145 expression and discovered TGFβ as a candidate, concurring 
with reports in pulmonary and coronary artery SMC [44,56]. One of these studies clearly 
demonstrated rapid transcriptional induction of miR-143/145 and increased contractile gene 
expression genes by TGFβ in human pulmonary artery SMC, and importantly, this was 
specific to SMC of human, but not rodent origin [44]. Furthermore, in our study, treatment of 
ND-SMC with TGFβ increased spread cell area and reduced proliferation similar to levels 
observed in T2DM-SMC; effects rescued by miR-143+145 knockdown. Elevated plasma 
levels of TGFβ in T2DM patients in vivo [40,57,58] may therefore augment vascular 
dysfunction evident in this patient group, at least in part through elevating miR-143/145 
expression. Inhibition of TGFβ signalling through Smad3 failed to re-establish a ND 
phenotype in T2DM-SMC, indicating that continued TGFβ signalling in T2DM cells is not 
required for these sustained phenotypic differences that more likely arose from earlier in vivo 
TGFβ exposure. This concept was confirmed by our data revealing a persistent effect of 
TGFβ on cell morphology that was retained for a week following its withdrawal. Additionally, 
secretion of TGFβ from cultured ND- and T2DM-SMC was similar (data not shown).  
 To examine the persistent nature of TGFβ stimulation further we also monitored miR-
143/145 levels following the removal of TGFβ. In this case, and in contrast to the effects on 
cell morphology, expression of miR-143/145 returned towards baseline levels. It is possible 
that exposure time of greater than a week would be necessary to confer a prolonged 
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upregulation of miR-143/145. Indeed, in terms of the progression of T2DM it is likely that 
patients endure elevated TGFβ levels for months or years (a scenario that is difficult to 
model in vitro), which may inflict persistent upregulation of miR-143/145. Whilst in our study 
we clearly demonstrated that miR-143/145 does drive TGFβ-mediated cellular effects (i.e. 
they were abrogated by antimiR transfection), the diabetic milieu is complex and other 
factors are likely to act in concert with TGFβ in vivo in maintaining elevated miR-143/145 
expression as we observed in native T2DM cells. 
  
4.6 Clinical Perspective  
Effective adaptation to arterial environments after grafting  is a key determinant of SV graft 
patency [11] and hence the ability of SMC to retain plasticity during this early phase of 
adaptation and “arterialisation” is of major importance. We have revealed a distinct and 
persistent phenotype of T2DM-SMC possessing characteristics in common with both 
classically differentiated and dedifferentiated SMC that would potentially compromise this 
plasticity. Owing to the silent, progressive nature of insulin resistance leading to T2DM, the 
vasculature is exposed to circulating metabolic disturbances for a prolonged period. Clinical 
data unequivocally illustrate the harmful nature of metabolic memory and have led to intense 
activity aimed at deciphering the underlying molecular mechanisms [59]. For example, even 
transient exposure to high glucose appears sufficient to impose long-term changes in gene 
expression in cultured vascular endothelial cells [60]. Our data indicate that elevated levels 
of miR-143/145 in human SV-SMC induced by diabetogenic stimuli such as TGFβ may 
represent one such mechanism (summarised in Figure 7). Species and tissue specificity is 
undoubtedly an important aspect of miR expression; defining potential disparate functions of 
individual miRs according to pathophysiology and/or cell type are key considerations [24].  
Therapeutic manipulation of miR-143/-145 in SV-SMC may therefore provide a novel 
opportunity to erase metabolic memory and restore vascular function in T2DM patients. 
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FIGURE 1. Differential morphology and miR expression of SV-SMC from non-diabetic
and type 2 diabetic patients. (A) Representative phase contrast images of SV-SMC. Cells
from non-diabetic patients (ND) show typical spindle-shaped morphology whereas those from
patients with type 2 diabetes (T2DM) exhibit a more rhomboid morphology. Scale bar =100
µm. (B) Frequency distribution of cell areas in 1000 µm2 intervals and (C) mean cell areas
(***P<0.001, n=15 patient donors each). (D) RT-PCR analysis of relative expression of
ACTA2 mRNA in SV-SMC. Normalized to GAPDH, P=0.286, n=20 patient donors each. (E)
Relative expression of miRs in SV-SMC from 10 non-diabetic (open bars) and 10 diabetic
(closed bars) patients. Normalized to U6 (*P<0.05, ns=not significant). (F) Two-tailed Pearson
correlation of relative expression of miR-143 and miR-145 in SV-SMC from same 10 non-
diabetic (open circles) and 10 diabetic (closed circles) patients. P<0.001, r2=0.6197.
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FIGURE 2. Effect of altering miR-143 and miR-145 levels on SV-SMC morphology
and function. (A) Cell areas of ND-SMC transfected with premiR negative (-ve) or
premiR-143/145 separately and in combination (***P<0.001, ns=not significant, n=4
patient donors). (B) Representative phase contrast images (upper panel, scale bar = 100
µm) or rhodamine phalloidin staining (lower panel, scale bar = 50 µm) of SV-SMC from 2
different non-diabetic patients transfected with premiR negative (-ve) or premiR-143/145
separately and in combination. (C) Cell areas of T2DM-SMC transfected with antimiR
negative (-ve) or antimiR-143/145 separately and in combination (***P<0.001, **P<0.01,
ns=not significant, n=4 patient donors).
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(D) Representative phase contrast images (upper panel, scale bar = 100 µm) or
rhodamine phalloidin staining (lower panel, scale bar = 50 µm) of SV-SMC from 2
different diabetic patients transfected with antimiR negative (-ve) or antimiR-143/145
separately and in combination. (E,F) SV-SMC were transfected with negative control
premiR/antimiR (-ve) or relevant premiRs or antimiRs, and cultured for 3 days prior to
determining initial cell counts. Cells were then placed into full growth media for a further 4
days before final cell counts (day 4). Data expressed as difference in absolute cell
number between final counts and initial counts. (E) Proliferation of premiR-transfected ND
cells. (F) Proliferation of antimiR-transfected T2DM cells (*P<0.05, ns=not significant, n=6
patient donors each).
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Figure 3
FIGURE 3. Identification of miR-143/145 targets in SV-SMC. (A) SMC were transfected with
premiRs (ND-SMC) or antimiRs (T2DM-SMC) for miR-143, miR-145, alone or in combination, or
negative controls, and whole cell homogenates prepared after 7 days (premiRs) or 10 days
(antimiRs). Representative immunoblots and pooled densitometry data for α-SMA, KLF4, IGF-1R,
myosin VI and GAPDH loading control (n=4 patient donors, *P<0.05, **P<0.01 vs. premiR -ve). (B)
Whole cell lysates were prepared from 20 ND- and 20 T2DM-SMC populations and immunoblotted for
α-SMA, (C) KLF4, (D) IGF-1R and (E) myosin VI (*P<0.05). Densitometry data normalized to GAPDH
loading control. (F) miR-143 and (G) miR-145 expression was analysed in RNA from the same
patients as the protein samples in panels B-G (*P<0.05).
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FIGURE 4. Effect of TGFβ on miR-143/145 expression, cell morphology and 
proliferation. (A,B) ND-SMC were treated with high glucose (25 mM), insulin (100 nM), IL-
1α and TNF-α (both 10 ng/mL) or TGFβ (10 ng/mL) for 48 h, and expression of miR-145 and 
miR-143 analyzed by RT-PCR (***P<0.001, ns=not significant, n=5 patient donors). (C) 
Quantification of cell areas of ND-SMC treated with 1 ng/mL TGFβ (***P<0.001, n=5 patient 
donors). (D) Representative phase contrast images of cells from same experiment (scale bar 
= 100 µm). (E) Rhodamine phalloidin staining of control and TGFβ-treated cells (scale bar = 
50 µm). (F) Proliferation of ND-SMC cells treated with or without 1 ng/ml TGFβ (*P<0.05, 
n=5 patient donors).  
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Figure 5
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FIGURE 5. Effect of modulating TGFβ signaling on cell morphology and function. (A) 
ND-SMC were transfected with antimiR negative (-ve) or antimiR-143+145. After 72h, 
transfected cells were treated with TGFβ (1 ng/mL in 10% FCS media) for 48 h, and cell 
area measured (**P<0.001, ns=not significant, n=6 patient donors). (B) Representative 
images of cells from same experiment (scale bar = 100 µm). (C) Cells were transfected with 
antimiR-ve or antimiR-145. After 72 h, cells were counted (day 0) and remaining cells treated 
with TGFβ (1 ng/ml) or vehicle for 96 h, and cells counted again. Data are represented as 
the increase in cell number (**P<0.01, ns=not significant, n=6 patient donors). (D) TGFβ 
signaling was blocked using TGFβRII neutralizing antibody (ab). Confluent cells were treated 
with TGFβ (1 ng/mL) for 20 min following a 1 h pre-treatment with anti-TGFβRII ab (10 
µg/mL). Cells were harvested and immunoblotted for phosphorylation of Smad3 or GAPDH 
(loading control). (E) T2DM-SMC were treated with  TGFβRII neutralizing ab (10 µg/mL) or 
control IgG for 48 h in 10% FCS media, and cell area measurements taken (ns=not 
significant, n=4 patient donors). (F) Representative images from the same experiment (scale 
bar = 100 µm). (G) Following the same treatment, F-actin cytoskeleton was visualized using 
rhodamine phalloidin. Representative images, scale bar = 50 µm. (H) For proliferation, 
quiesced cells were treated with 10 µg/mL TGFβRII neutralizing ab or control IgG for 96 h in 
10% FCS media prior to cell counting (ns=non-significant, n=4 patient donors). (I) 
Expression levels of miR-145 and miR-143 following 48 h treatment with 10 µg/mL TGFβRII 
neutralizing ab or control IgG (ns=non-significant, n=4 patient donors). 
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FIGURE 6. Prolonged effect of TGFβ on ND-SMC phenotype. ND-SMC were cultured for 7 days
with 1ng/mL TGFβ or vehicle control, and then for a further 7 days in media with no treatment. Cell
areas, miR-143 and miR-145 expression were monitored on days 7, 11 and 14. Data are expressed
as fold increase in cells cultured with TGFβ for 7 days relative to vehicle-treated cells maintained for
the same time period (dotted line). (A) Fold-induction in spread cell area at each time point (n=4). (B)
Representative phase contrast images of ND-SMC from the same experiment (scale bar = 100 µm).
(C) Induction of miR-143 expression (n=4) and (D) miR-145 expression in the same cells (n=4).
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Figure 7
FIGURE 7. Summary Figure. Stimuli associated with type 2 diabetes (e.g. TGFβ) drive
persistent increases in expression of miR-143 and -145 in SV-SMC. Increased miR-145
levels reduce SV-SMC proliferation, whilst increases in either miR-143 or -145 levels lead to
increased cell area and truncated F-actin. Broken arrows indicate a proposed association
based upon our data and literature within the discussion.
Cell area ↑ Truncated
F-actin ↑ α-SMA↑
Cell 
proliferation↓KLF4↓Myosin VI ↓
Diabetic stimuli, e.g. TGFβ
Diabetic stimuli, e.g. TGFβ
miR-145 ↑
miR-143 ↑
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Supplementary Figure 1
SUPPLEMENTARY FIGURE 1. Differential cytoskeletal morphology and proliferation 
rate of SV-SMC from non-diabetic and type 2 diabetic patients. (A) Representative 
images showing rhodamine phalloidin staining of F-actin filaments in SV-SMC from 2 non-
diabetic and 2 diabetic patients. Scale bar = 20 µm. (B) 7-day proliferation profiles of ND- 
and T2DM-SMC (two-way ANOVA: P<0.001, Bonferroni post-hoc: *P<0.05, n=6 patient 
donors each).  
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SUPPLEMENTARY FIGURE 2. Effect of long-term culture on miR-145 and miR-143 expression. SMC from 4 ND and 4 T2DM patients were 
maintained in long-term culture (up to 4 months), passaging as required; RNA was extracted at each confluent passage (P2-P6). miR-145/143 
expression levels were determined by real-time PCR. (A) Expression of miR-145 and (B) miR-143 in ND and T2DM SV-SMC. All non-significant, 
one-way repeated measures ratio ANOVA. Average miR-145 and miR-143 expression levels remained elevated in T2DM versus ND SMC.
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SUPPLEMENTARY FIGURE 3. Initial identification of miR-143/145 targets in SV-SMC. SV-SMC were transfected with premiR or antimiR-
143+145 together (+) or negative controls (-), and whole cell homogenates prepared 3, 5, 7 and 10 days post-transfection. Immunoblots and 
pooled densitometry data for potential targets of miR-143/145. (A) CamKII, (B) IRS-1, (C) PKC-, (D) GAPDH loading control (all n=3 patients). 
The effect of premiR-143/145 or antimiR-143/145 transfection compared to controls was not statistically significant at any timepoint.
Supplementary Figure 3
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SUPPLEMENTARY FIGURE 4. Initial identification of miR-143/145 targets in SV-SMC. SV-SMC were transfected with premiR or antimiR-
143+145 together (+) or negative controls (-), and whole cell homogenates prepared 3, 5, 7 and 10 days post-transfection. Immunoblots and 
pooled densitometry data for potential targets of miR-143/145. (A) α-SMA, (B) KLF4, (C) IGF-1R, (D) Myosin VI, (E) GAPDH loading control (all 
n=3 patients). The effect of premiR-143/145 or antimiR-143/145 transfection compared to controls was not statistically significant at any 
timepoint.
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